Oxford BioDynamics PLC 2022 AR2
The report highlights Oxford BioDynamics Plc's commercial progress in fiscal year 2022, notably the launch of its flagship product, EpiSwitch CiRT, in the US and UK markets. The company expanded its commercial footprint by opening US offices in Gaithersburg, Maryland, and raising £3.62 million in October 2021, followed by a post-year-end fundraising of £9.3 million in October 2022. Financially, the company reported revenue of £0.2 million and an operating loss of £8.6 million due to continued investment in commercialization. Oxford BioDynamics also advanced its research collaborations, including participation in the FNIH PACT and HIPPOCRATES consortia.
Company: Oxford BioDynamics PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2022
Type: AR2
Pages: 118
Back to company
Oxford BioDynamics PLC
Annual Report And Accounts
The report highlights Oxford BioDynamics Plc's commercial progress in fiscal year 2022, notably the launch of its flagship product, EpiSwitch CiRT, in the US and UK markets. The company expanded its commercial footprint by opening US offices in Gaithersburg, Maryland, and raising £3.62 million in October 2021, followed by a post-year-end fundraising of £9.3 million in October 2022. Financially, the company reported revenue of £0.2 million and an operating loss of £8.6 million due to continued investment in commercialization. Oxford BioDynamics also advanced its research collaborations, including participation in the FNIH PACT and HIPPOCRATES consortia.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Oct 1, 2021 - Sep 30, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees